Finding a cure through funding vital research
There are currently very few treatments showing any efficacy (scientifically documented and proven) and no cure available for DIPG
Research initiatives and funding of this work enabling doctors to get a better understanding of how DIPG develops and progresses, is the only way to lead development of effective treatment options, and techniques to benefit ALL children affected by DIPG.
Here are some of the latest developments :
Sydney researchers identify/advance potential revolutionary new drug treatment for fatal childhood cancer
Electrical and synaptic integration of glioma into neuronal circuits
Release from the ICR regarding the first EVER specifically designed and 'targeted' therapy to treat DIPG patients with mutations in the ACVR1 gene.
ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma
ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis
Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma
Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma
Results from the MSKCC: Convection-enhanced delivery for diffuse intrinsic pontineglioma: a single-centre, dose-escalation, phase 1 trial
Potent antitumor efficacy of Anti-GD2 CAR-T cells in H3 K27M +diffuse midline gliomas
Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma
Study splits incurable childhood brain tumours into 10 new diseases
Targeting a protein called neuroligin-3
Influence of an intratumoral cyst on drug distribution by convection-enhanced delivery: case report
Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management
Restoring the tumor suppressor gene p16 slows tumor growth in vitro
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
BMI-1 is a Potential Therapeutic Target in Diffuse Intrinsic Pontine Glioma
A phase I study of convection enhanced delivery (CED) of 124I-8H9 radio-labeled monoclonal antibody in children with diffuse intrinsic pontine glioma (DIPG).
External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry.
Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma
Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models